Vasodilatation to arachidonic acid in humans. An insight into endogenous prostanoids and effects of aspirin
- PMID: 7554190
- DOI: 10.1161/01.cir.92.8.2113
Vasodilatation to arachidonic acid in humans. An insight into endogenous prostanoids and effects of aspirin
Abstract
Background: Human endothelial and vascular smooth muscle cells synthesize prostanoids. Several of these have been implicated in the physiological and pathophysiological regulation of vascular tone; however, there is no direct evidence that human blood vessels synthesize sufficient prostanoid to alter vessel tone.
Methods and results: We explored the effects of local infusions of arachidonic acid on the tone of preconstricted superficial hand veins in healthy volunteers. Aspirin was used to assess the contribution of prostanoids to the responses seen. Local infusion of arachidonic acid produced a dose-dependent dilatation of preconstricted veins. This was abolished by local infusion of aspirin. Oral aspirin was also effective: a high (anti-inflammatory) dose of aspirin (1 g) taken 2 hours before the experiment blocked the arachidonic acid-induced venodilatation; however, a low (cardioprotective) dose of aspirin (75 mg) did not. Unlike the responses to arachidonic acid, responses to glyceryltrinitrate and bradykinin were unaltered by aspirin (1 g). Ex vivo platelet aggregation was inhibited by aspirin in both high and low doses. Aspirin (1 g) inhibited arachidonic acid-induced venodilatation for up to 5 days. The time course was similar for vascular and platelet effects.
Conclusions: The present findings demonstrate that local generation of prostanoids in a human vessel in vivo alters vascular tone. The predominant prostanoid synthesized is a dilator and its synthesis can be blocked by an anti-inflammatory but not a cardioprotective dose of aspirin. The results suggest that selective inhibition of platelet aggregation by oral aspirin might be a function of dose rather than the interval between doses.
Similar articles
-
Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.Circulation. 2001 Aug 14;104(7):820-5. doi: 10.1161/hc3301.092790. Circulation. 2001. PMID: 11502709
-
Ascorbic acid-induced modulation of venous tone in humans.Hypertension. 2001 Mar;37(3):949-54. doi: 10.1161/01.hyp.37.3.949. Hypertension. 2001. PMID: 11244023
-
Relative effects of aspirin on platelet aggregation and prostaglandin-mediated coronary vasodilatation in the dog.Circulation. 1980 Dec;62(6):1221-7. doi: 10.1161/01.cir.62.6.1221. Circulation. 1980. PMID: 7438358
-
Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.Semin Thromb Hemost. 1997;23(4):349-56. doi: 10.1055/s-2007-996108. Semin Thromb Hemost. 1997. PMID: 9263351 Review.
-
Vascular smooth muscle, endothelial regulation and effects of aspirin in hypertension.Front Biosci. 1998 Apr 27;3:e23-38. doi: 10.2741/a365. Front Biosci. 1998. PMID: 9556499 Review.
Cited by
-
Metabolic modulation of sympathetic vasoconstriction in human skeletal muscle: role of tissue hypoxia.J Physiol. 2000 Sep 1;527 Pt 2(Pt 2):387-96. doi: 10.1111/j.1469-7793.2000.00387.x. J Physiol. 2000. PMID: 10970439 Free PMC article. Clinical Trial.
-
Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU).BMJ. 2017 Nov 24;359:j5157. doi: 10.1136/bmj.j5157. BMJ. 2017. PMID: 29175902 Free PMC article. Clinical Trial.
-
Vasodilatation in response to repeated anodal current application in the human skin relies on aspirin-sensitive mechanisms.J Physiol. 2002 Apr 1;540(Pt 1):261-9. doi: 10.1113/jphysiol.2001.013364. J Physiol. 2002. PMID: 11927685 Free PMC article.
-
Bioactive Lipid Signaling in Cardiovascular Disease, Development, and Regeneration.Cells. 2020 Jun 3;9(6):1391. doi: 10.3390/cells9061391. Cells. 2020. PMID: 32503253 Free PMC article. Review.
-
Epicardial adipose tissue thickness as a predictor of impaired microvascular function in patients with non-obstructive coronary artery disease.J Nucl Cardiol. 2013 Oct;20(5):804-12. doi: 10.1007/s12350-013-9739-6. Epub 2013 Jun 8. J Nucl Cardiol. 2013. PMID: 23749262
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources